Skip to content

Vaxcyte, Inc. PCVX Price / book

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
Moderna logo
ModernaMRNA
2.7×+1.6×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
5.9×+0.6×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
5.9×-1.7×

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Calculated from Vaxcyte, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s price / book?
Vaxcyte, Inc. (PCVX) reported price / book of 2.8× in Q1 2026.
How has Vaxcyte, Inc.'s price / book changed year-over-year?
Vaxcyte, Inc.'s price / book increased by 83.7% year-over-year, from 1.5× to 2.8×.
What is the long-term trend for Vaxcyte, Inc.'s price / book?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s price / book has grown at a -10.6% compound annual growth rate (CAGR), from 3.9× to 2.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.